The first oral session in the acute myeloid leukemia (AML) translational research track of June 15, was given by Eliza Yankova, from the University of Cambridge, who presented collaborative studies done together with Storm Therapeutics Ltd. outlining pharmacological inhibition of METTL1 as a therapeutic strategy in AML treatment. Read More
Researchers from Lund University presented data from a study that aimed to identify novel targets for immunotherapy in acute myeloid leukemia (AML). To identify differentially expressed cell surface proteins in the primitive CD34+CD38- cell populations, an arrayed antibody screen was performed on primary bone marrow samples from patients with AML as well as healthy donors. Read More
Inflammatory bowel disease (IBD) is sometimes associated with spondyloarthritis (SpA) and it highly impacts patients’ quality of life. It is crucial to understand the pro-inflammatory processes that take place during the pathogenesis of IBD-associated SpA. Read More
The immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein VAV1 plays a key role in mediating T-cell receptor (TCR) and B-cell receptor (BCR) activity and signaling. Read More
The overexpression of choline-kinase alpha (CKα) promotes aberrant choline metabolism in epithelial ovarian cancer, thus increasing phosphocholine- and total choline-containing compounds. Previous findings had shown that silencing CKα impacted cell proliferation, migration and invasion, and CKα was hypothesized to be a potential new therapeutic target for ovarian cancer. Read More
Zymeworks Inc. has obtained IND clearance from the FDA for ZW-171, a novel T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. Clinical development will begin this year, and additional applications will be filed in the second half of the year seeking trial clearances in other territories. Read More
Researchers at Rheinisch-Westfaelische Technische Hochschule Aachen University and University of Arizona have synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a DYRK1A and/or DYRK1B and/or DYRK2 and/or DYRK3 and/or CLK1 and/or CLK2 and/or CLK3 and/or CLK4 and/or HASPIN targeting moiety through a linker reported to be useful for the treatment of cancer, viral infection, diabetes, inflammatory disorders, Alzheimer’s, Parkinson’s, Huntington’s and autoimmune diseases, among others. Read More
Genescience Pharmaceuticals Co. Ltd. has identified melanocortin MC4 receptor antagonists reported to be useful for the treatment of cachexia, anorexia nervosa, nausea and vomiting, sarcopenia, neuropathic pain, post-traumatic stress disorder and muscle and bone disorders. Read More
Amarna Therapeutics BV is advancing Nimvec AM-510 gene therapy for type 1 diabetes and has formed a scientific advisory board to guide development. Read More
Addex Pharma SA has divulged metabotropic glutamate mGlu7 receptor negative allosteric modulators reported to be useful for the treatment of pain, ear disorders and neurological disorders. Read More
Trio Medicines Ltd. has described β2-adrenoceptor (ADRB2) antagonists reported to be useful for the treatment of cancer, cerebral cavernous malformations, chronic heart failure, chronic obstructive pulmonary disease, hereditary hemorrhagic telangiectasia, migraine and asthma. Read More
Enveda Biosciences (Enveda Therapeutics Inc.) has announced a new series B2 financing round of $55 million. The drug discovery and development company uses artificial intelligence (AI)-powered technologies to translate nature into new medicines. Read More
